STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 February 2001 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
On 17 August 1998 the Marketing Authorisation Holder submitted to the EMEA nine applications for 
Type I variations (I/01-09) in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995,  as  amended.  These  variations  were  related  to  changes  in  the  qualitative  composition  of  the 
immediate packaging material, a change in the batch size of the finished product, an extension of the 
retest  period  of  the  active  substance  and  minor  changes  of  the  manufacturing  process  of  the  active 
substance. The variations were approved by the EMEA on 23 September 1998 and did not require any 
amendments to the Commission Decision.  
On 8 January 1999 the Marketing Authorisation Holder submitted to the EMEA five applications for 
Type I variations (I/10-14) in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995, as amended. These variations were related to a change in the manufacturing authorisation and to 
changes in the test procedures of the active substance. The variations were approved by the EMEA on 
8 February 1999 and did not require any amendments to the Commission Decision.  
On  14  June  1999  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an  application  for  a 
Type  II  variation  (II/15)  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March 
1995,  as  amended.  This  application  was  related  to  the  update  of  the  Summary  of  Product 
Characteristics  (SPC)  and  of  the  Package  Leaflet  on  the  basis  of  the  results  of  interaction  studies 
performed with compounds inhibiting or inducing CYP 3A4. Repaglinide ATC code was also changed 
from  A10B  H01  to  A10X02.  The  CPMP  adopted  on  23  September  1999  a  positive  Opinion  on  this 
Type 
on  
II 
20 January 2000 
the  European  Commission 
the  Decision 
amended 
variation 
and 
On 15 September 1999 the Marketing Authorisation Holder submitted to the EMEA five applications 
for  Type  I  variations  (I/17-21)  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended. These variations were related to changes to extend the retest period of the 
active substance, to changes in in-process controls applied during the manufacture, to a change in the 
test  procedure  of  the  active  substance  and  to  an  extension  of  the  shelf  life.  These  variations  were 
approved by the EMEA on 20 October 1999. Four of these variations did not require any amendments 
to the Commission Decision, and one of them (extension of the shelf life) required an amendment to 
the SPC. The European Commission amended the Decision on 13 December 1999. 
On 2 November 1999 the Marketing Authorisation Holder submitted to the EMEA an application for a 
Type  II  variation  (II/22)  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March 
1995,  as  amended.  The  scope  of  this  variation  was  to  change  the  manufacturing  site  of  the  active 
substance  and  a  change  in  the  manufacturing  process.  The  CPMP  adopted  on  19  January  2000  an 
Opinion on this Type II variation and a favourable Decision was issued by the European Commission 
on 22 February 2000. 
On 28 March 2000 the Marketing Authorisation Holder submitted to the EMEA three applications for 
Type I variations (I/23-25) in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995,  as  amended.  These  variations  were  related  to  changes  in  the  test  procedures  of  the  medicinal 
product and to a change in the specifications of the medicinal product. The variations were approved 
by the EMEA on 26 April 2000 and did not require any amendments to the Commission Decision.  
On 8 September 2000 the Marketing Authorisation Holder submitted to the EMEA an application for a 
Type  II  variation  (II/26)  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March 
1995, as amended. The scope of this variation was to update the SPC (section 4.3) and Package Leaflet 
based  on  the  results  of  a  renal  efficacy  and  safety  study  and  to  update  the  SPC  (section  4.8)  and 
Package  Leaflet  with  regards  to  information  on  hepatic  dysfunction.  The  CPMP  adopted  on  16 
November  2000  an  Opinion  on  this  Type  II  variation  and  a  favourable  Decision  was  issued  by  the 
European Commission on 5 March 2001. 
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
• 
On 5 October 2000 the Marketing Authorisation Holder submitted to the EMEA four applications for 
Type I variations (I/27-30) in accordance with Commission Regulation (EC) No. 542/95 of 10 March 
1995, as amended. These variations were related to extension of the shelf life, change in the container 
shape,  change  in  the  qualitative  composition  of  immediate  packaging  material,  and  change  of  the 
manufacturing  site  for  part  or  all  of  the  manufacturing  process  of  the  medicinal  product.  These 
variations were approved by the EMEA on 7 November 2000. Three of these variations did not require 
any amendments to the Commission Decision, and one of them (extension of the shelf life) required an 
amendment to the SPC. The European Commission amended the Decision on 22 January 2001. 
2/2 
EMEA 2004 
 
 
 
 
 
 
 
